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Abstract
Growing evidence indicates that reduced uterine perfusion pressure (RUPP) triggers the cascade of events leading
to preeclampsia. Edaravone is a powerful free radical scavenger used for the treatment of ischemia/reperfusion
diseases due to its anti-oxidative stress and anti-inflammatory properties. Here we investigate the effect of
edaravone (3 mg/kg) on different maternal and fetal outcomes of RUPP-induced placental ischemia mice model.
RUPP surgery was performed on gestation day (GD) 13 followed by edaravone injection from GD14 to GD18,
sacrifice day. The results showed that edaravone injection significantly decreased the maternal blood pressure
(113.2 ± 2.3 mmHg) compared with RUPP group (131.5 ± 1.9 mmHg). Edaravone increased fetal survival rate (75.4%)
compared with RUPP group (54.4%), increased fetal length, weights, and feto-placental ratio (7.2 and 5.7 for RUPP
and RUPP-Edaravone groups, respectively) compared with RUPP group. In addition, RUPP resulted in many fetal
morphological abnormalities as well as severe delayed ossification, however edaravone decreased the
morphological abnormalities and increased the ossification of the fetal endoskeleton. Edaravone improved the
histopathological structure of the maternal kidney and heart as well as decreased the elevated blood urea and
creatinine levels (31.5 ± 0.15 mg/dl (RUPP), 25.6 ± 0.1 mg/dl (RUPP+edaravone) for urea and 5.4 ± 0.1 mg/dl (RUPP),
3.5 ± 0.1 mg/dl (RUPP+edaravone) for creatinine) and decreased cleaved caspase-3 expression in the maternal
kidney. In conclusion, this study demonstrated that our RUPP mice model recapitulated preeclampsia symptoms
and edaravone injection ameliorated most of these abnormalities suggesting its effectiveness and potential
application in preeclampsia treatment regimes.
Keywords: Preeclampsia, RUPP, Edaravone, Placental ischemia, Endoskeleton, Fetal growth restriction
Background
Reduced placental blood flow leads to placental ische-
mia, an initiating event in the pathophysiology of pre-
eclampsia [11]. The pathogenesis of preeclampsia is
related to trophoblast invasion suppression leading to in-
complete spiral artery remodeling and decreased blood
flow to the placenta (Stage 1 of preeclampsia) which
results in placental hypoxia/ischemia and poor placental
growth (stage 2) [15, 58]. All these changes cause oxida-
tive stress in placental villi [20], which contribute to ma-
ternal endothelial dysfunction, leading to hypertension,
renal impairment, proteinuria, and perinatal death [30].
Intrauterine fetal growth restriction has been associated
with preeclampsia which occurs due to the insufficient
supply of oxygen and/or nutrients to the fetus [43]. Cur-
rently, there are no effective treatments for preeclamp-
sia, except for the delivery of babies, however, premature
delivery often causes severe complications in the neo-
nates [50].
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The reduced uterine perfusion pressure (RUPP) model
is a well-characterized animal model of preeclampsia
[11, 27, 32] which has been reported to manifest symp-
toms related to preeclampsia such as increased maternal
blood pressure, increased serum sFlt-, proteinuria,
endotheliosis and decreased fetal weight [17, 23]. Add-
itionally, it has been reported that RUPP model is also a
model of oxidative stress observed during preeclampsia
[40]. Thus, the RUPP model is ideal to understand
pathophysiological mechanisms underlying preeclampsia
associated with placental ischemia [11].
Uteroplacental ischemia results in hypoxia due to
reduced blood flow to the placenta and developing fe-
tuses. As a result, the production of free radicals and
ROS is increased, causing excessive apoptosis of
trophoblast cells and endothelial dysfunction. Based
on the fact that oxidative stress plays important role
in the pathogenesis of preeclampsia [37], the authors
discussed the preventive and therapeutic potential of
some antioxidants, such as Vitamin E and C in pre-
eclampsia. Moreover, Ushida et al. [50] reported that
the administration of H2, a novel antioxidant, im-
proved the placental ischemia-induced hypertension,
angiogenic imbalance, and oxidative stress.
Edaravone (3-methyl-1-phenyl-2-pyrazolin-5-one,
synonyms MCI-186) is a potent free radical scavenger
[28] whose administration was found to improve
ROS-induced tissue damage [47]. It has protective ef-
fects mainly against oxidative stress-induced neurode-
generative diseases [34], however, studies have
demonstrated its effectiveness in other tissues [22, 24,
49, 56]. Moreover, Zhao et al. [58] demonstrated that
edaravone decreased ROS production and sFlt-1 se-
cretion in an in vitro model of placental hypoxia and
suggested that edaravone can be used as a therapeutic
target for the prevention of preeclampsia. Conse-
quently, the aim of the present study was to investi-
gate, for the first time, whether in vivo administration
of edaravone could improve maternal and fetal patho-
physiological characteristics related to preeclampsia
using the RUPP mice model.
Materials and methods
Animals
All animal experiments were performed in compliance
with a protocol approved by the Animal Committee of
the Graduate School of Medicine and Dentistry, Oka-
yama University (OKU-2019677). Healthy mature virgin
females and fertile males of C57BL/6 N mice (22 ± 2 g,
8 ± 1 week old) were purchased from SLC, Japan (Shizu-
oka, Japan). The mice were housed in a temperature-
regulated room (23–25 °C) with free access to food and
water, under a 12 h light/12 h dark cycle.
RUPP surgery as a model to induce placental ischemia
To induce placental ischemia, the reduced uterine perfu-
sion pressure (RUPP) model was adopted with a modifi-
cation from Janot et al. [25]. Mating (2 females/1 male)
was achieved. The day at which vaginal plug was located
has been considered as day zero of pregnancy. Gestation
day (GD)13 was determined to be the RUPP surgery day
and GD18 was determined as the end point for
experimentation.
On GD13, an inhalation mask was used to anesthetize
the animals with a mixture of nitrous oxide/oxygen/iso-
flurane (69%/30%/1%) during surgical preparation. Body
temperature was monitored and maintained at 37 °C. A
2 cm midline abdominal incision was performed to ex-
pose the uterine horns and their vascularization, live and
dead fetuses were counted within the uterine horns, and
surgery was performed. After trying many ligation
places, it was found that ligation of uterine vessels in the
middle of each uterine horn was suitable as described by
Janot et al. [25]. Other ligation places resulted in either
maternal death, maternal abortion, or complete fetal re-
sorption. Briefly, the uterine vessels (artery and vein)
were ligated (6–0 silk) at the central part of each uterine
horn (Fig. 1a&b). Pregnant mice from sham-vehicle and
sham-edaravone groups underwent sham procedure
without ligation. After that, the uterus was placed back
into the abdominal cavity, the abdominal wall was su-
tured, and the animals were housed individually and
monitored. Maternal body weight was monitored from
GD13 to GD18.
Measuring the uterine blood flow
Blood flow (BF) values in both the right and left uterine
arteries were obtained before and immediately after li-
gating uterine vessels. Blood flow was measured with a
laser-Doppler flowmeter (FLO-C1, 97 Omegawave,
Tokyo, Japan). A laser Doppler 98 flowmetry probe was
fixed perpendicular to the uterine arteries where BF
values were measured uninterrupted for five minutes.
Three values were recorded at each artery. After ligation,
BF values were rerecorded at the same places for an-
other five minutes uninterrupted. The mean BF value
was recorded and percentage of decreased BF after
ligation was calculated.
Experimental groups and treatment
The pregnant mice were divided into four groups (each
n = 8), as follows:
1. Sham-vehicle (SV) group, sham procedure plus i.v.
injection of 0.3 ml saline.
2. Sham-Edaravone (SE) group, sham procedure plus
i.v. injection of 0.3 ml edaravone (Mitsubishi
Tanabe Pharma, 3 mg/kg).
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3. RUPP-vehicle (RV) group, surgery with ligation of
both uterine vessels plus i.v. injection of 0.3 ml
saline.
4. RUPP-Edaravone (RE) group, surgery with ligation
of both uterine vessels plus i.v. injection of 0.3 ml
edaravone (Mitsubishi Tanabe Pharma, 3 mg/kg)
(Fig. 1c).
The edaravone dose was chosen after trying different
doses; 3 mg/kg, 30 mg/kg and 100 mg/kg. It was found
that the dose of 3 mg/kg had no adverse effects on the
developing fetuses, however, the higher doses resulted in
increased fetal loss. This dose was proven to be effective
in many ischemic models [42]. All injections were done
via the tail vein from GD 14 to GD 18. This study was
based on 42 adults (32 females and 10 males) and 239
fetuses.
Blood pressure of conscious pregnant mothers was
evaluated by recording the systolic blood pressure (SBP),
diastolic blood pressure (DBP) and mean blood pressure
(MBP) (mmHg) using a noninvasive tail-cuff method
(BP-98A; Softron, Japan) [17].
Maternal and fetal sampling
On GD 18, the pregnant females were decapitated under
deep anesthesia by i.p. injection of pentobarbital (40 mg/
kg), subjected to caesarian section, then the whole uterus
with fetuses were removed and embryotoxicity was ini-
tially assessed by counting the number of live, resorbed
and dead fetuses. Resorbed fetuses are those who are
disintegrated and assimilated in the uterus after the
completion of organogenesis. Dead or stillbirth fetuses
were distinguished from live fetuses in terms of colour
(normal pink vs. brown, green, black), movement and
body consistency (normal, dry or soft). Live fetuses were
anaesthetized by isoflurane and examined grossly for in-
vestigating the morphological abnormalities.
Fig. 1 a Ligation of the two uterine vessels was performed in pregnant mice of experimental groups around the middle of each uterine horn. b
Schematic description of the surgery. c Experimental groups included SV, sham surgery plus i.v. injection of 0.3 ml saline. SE group, sham surgery
plus i.v. injection with 0.3 ml edaravone (3 mg/kg). RV group surgery with ligation of both uterine vessels plus i.v. injection of 0.3 ml saline. RE
group surgery with ligation of both uterine vessels plus i.v. injection of 0.3 ml edaravone (3 mg/kg). All injections started at GD14 and ended at
GD 18. F; fetus, K; kidney, Ov; ovary, Pl; placenta, Ut; uterine
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Fetal resorption and viability rates were calculated as
the number of fetuses counted on GD13 minus the
number of fetuses found on GD18 at the time of caesar-
ian section. Fetal body weight, crown-rump length and
placental weight were recorded in the four groups. Fe-
tuses were then photographed and after that eviscerated
and kept in 10% formalin for detection of endo-skeletal
malformations.
Biochemical, histopathological and immunohistochemical
analyses
Maternal serum was obtained via centrifugation of ma-
ternal blood sample (from heart and ventral aorta) at
3500 r.p.m. at 4 °C for 10 min, the supernatant was col-
lected and stored at − 80 °C [35]. For urea detection, a
commercial urea assay kit (Abcam ab83362) was used
according to manufacturer’s instructions. Serum creatin-
ine was measured using creatinine assay kit (Abcam
ab65340) according to manufacturer’s instructions. In
both tests, colour was detected at OD of 570 nm.
For histopathology and immunohistochemistry, Mater-
nal kidney and heart were fixed in 4% paraformaldehyde,
cryoprotected in 30% sucrose, embedded and frozen at
− 80 °C. Transverse renal or longitudinal cardiac frozen
20 μ thickness sections were cut and stored in − 80 °C.
Hematoxylin and eosin staining was performed [21] and
photographed using Olympus microscope (BX51).
Immunohistochemical procedure was performed ac-
cording to Shang et al. [41], briefly, sections were incu-
bated with rabbit anti-caspase3 (1:300, Cell Signaling
Fig. 2 RUPP ischemia placental model decreases pregnant mother bodyweight gain and edaravone injection recovers body weight gain. a
Differences of body weight gain of pregnant mice relative to GD 13 from different groups. b Percentage of total body weight gain of pregnant
mice relative to GD13 body weight in different groups. RV mothers showed drastic decrease in their weight and couldn’t recover the initial
weight decrease after surgery. RE pregnant mice showed better weight gain recovery, though still less than that seen in control









Mean number of fetuses at surgery (GD13) 8 ± 1 7 ± 1 7 ± 1 8 ± 1
Mean number of fetuses at sacrifice (GD18) 7 ± 1 6 ± 1 4 ± 1 6 ± 1
Fetal Loss (2) 3.23% (3) 5.45% (26) 45.61% (16) 24.62%
Fetal absorption (2) 100% (2) 66.67% (18) 69.23% (11) 68.75%
Fetal death 0% (1) 33.33% (8) 30.77% (5) 31.25%
Fetal viability 96.77% 94.55% 54.39% 75.38%
Mean fetal crown-rump length (cm) 2.16 ± 0.081 2.03 ± 0.121 1.52 ± 0.089** 1.85 ± 0.151#
Mean fetal weight (g) 0.952 ± 0.017 0.888 ± 0.023 0.403 ± 0.025** 0.687 ± 0.017*#
Mean placental weight (g) 0.121 ± 0.004 0.117 ± 0.001 0.071 ± 0.003** 0. 096 ± 0.002*#
Mean fetal weight: placental weight 7.87 7.59 5.68 7.15
Data are represented as mean ± SD
* p < 0.05 ** p < 0.01 compared with the SV group
# p < 0.05 compared with RV group
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Technology, Danvers, MA) primary antibody overnight
at 4 °C, incubated with rabbit monoclonal biotinylated
secondary antibody (1:200; Vector Laboratories, Burlin-
game, CA) for 2 h. at RT. Immunoreactivity was devel-
oped using horseradish peroxidase streptavidin-biotin
complex solution (Vectastain ABC kit; Vector Laborator-
ies) for 30 min. and then incubated with DAB.
Endo-skeletal investigation of fetuses
For endo-skeletal preparation of fetus, double staining
transparency technique was applied using the Alcain
blue and Alzarin red S for staining cartilage and bone,
respectively [3]. Photographs were taken and lengths of
ossification centers within some bones were measured
using Fiji image J software.
Statistical analysis
All data sets were expressed as mean ± standard error
of the mean (SEM). The data were analyzed statisti-
cally for normal distribution (student’s T test) and
homogeneity of variances (Levene test) using statis-
tical package of social sciences (IBM SPSS) statistics
software for Windows, Version 22 (IBM Corp.,
Armonk, NY, USA). Differences were considered
Fig. 3 Pregnancy outcome of RUPP surgery and edaravone injection. a Representative photogrphs of uterine horns and fetuses from different
groups showing fetal resorption (arrow) and growth retardation of fetuses from RV group. b Embryo survival showed its least value in RV group
and increased after edaravone injection (RE) group. c Fetal loss is very high in RV group and decreased after edaravone injection. d Crown-rump
length of fetuses from different groups at GD18. e Fetal weight from different groups showing highly significant decrease in RV group. f Placental
weight from different groups. g Relationship between fetal to placental weight shows a highly significant decrease in RV group suggecting
placental insufficiency due to RUPP surgery. This ratio increased after edaravone injection
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insignificant whenever P > 0.05. The significances of
the obtained data were classified into two categories,
i.e., p < 0.05 and p < 0.01 according to the obtained p
values.
Results
RUPP surgery reduced the uterine artery blood flow
Ligation of uterine vessels in the middle of uterine horns
at GD13 resulted in dramatic decrease in the arterial
blood flow to mice fetuses with a percentage of 76.6%
(from 54.7 ± 2.7 mm/s to 12.9 ± 1.7 mm/s, p < 0.01) (Fig.
1S).
Body weight of mothers and uteri
Mothers from either SV or SE groups showed con-
tinuous progressive increase in their weight (Fig. 2a,
Table 1S) with a total weight gain percentage of 39
(SV) and 37.1 (SE) (Fig. 2b, Table 2S). On the other
hand, pregnant mice from RV group showed drastic
decline in their weight on the first day after surgery
(− 5.8 ± 0.2 g), after that their body weight increased
slowly in low values, however, they could not recover
the initial body weight loss after surgery with a final
percentage of body weight loss of − 6.4 (Fig. 2b, Table
2S). Contrarily, injection of edaravone to RUPP preg-
nant mice resulted in an increase in their body weight
and recovery of the initial body weight loss, though
still lower than the values of SV group (Fig. 2a, Table
1S) with a final net weight increase of 8.6 at the end
of the experiment (Fig. 2b, Table 2S).
Regarding the uterine horns weight, there was insig-
nificant difference between SV and SE groups. In con-
trast, pregnant mice from RV group showed a highly
significant decrease in the uterus weight (p < 0.01) with
Fig. 4 Representative photographs of macroscopic examination of GD18 fetuses from different groups. a&b normal morphology of fetuses from
SV and SE groups, respectively. c-h fetuses from RV group showing various morphological anomalies including microtia (arrowhead), syndactyly
(doubled arrow), kyphosis (asterisk), subcutaneous hemorrhage (thick arrow), unilateral microphthalmia (arrow) and small head (h). i fetus from RE
group showing improved morphology after edaravone injection
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almost 50% decline compared with SV group. Neverthe-
less, the uterine weight of RE mice increased signifi-
cantly compared with RV group, though it showed
significant decrease (p < 0.05) compared with SV group
with a reduction percentage of 17.3 (Table 3S).
Edaravone improves fetal growth and viability
The current study showed that RUPP placental ischemia
model induced a dramatic decrease in fetal viability with
increased percentage of fetal loss (45.6%) with more fetal
resorption than fetal death. Interestingly, RE mice
Fig. 5 Representative photographs of double stained endoskeleton of fetuses and their body parts from different groups. (A) Whole fetus
indicating severe loss of ossification in fetuses from RV group (A3). (B) Fetal skull showing well ossified bones in SV and SE groups (B1&2), while
only supra-occipital and mandible were ossified in RV group (B3) and its amelioration after edaravone group (B4). (C) sternum and sternabrae
ossification showing ossification of 6 segments in SV and SE groups (C1&2), 1st segment in RV group (C3) and first four segments in RE group
(C4). (D&E) Well-ossified forelimb and pectoral girdle (D) and hindlimb and pelvic girdle (E) in SV and SE groups (1&2), severe delayed ossification
in RV group (3) (asterisk) and amelioration after edaravone injection (4). (F) Ossification of lumbar and sacral vertebrae showing highly ossified
centra in SV and SE groups (F1&2), complete loss of ossification in RV group (F3), except small portion in the ilium (asterisk), moderate
amelioration after edaravone injection (F4). At, atlas; Cl, clavicle; ExO, exoccipital; Fr, frontal; Fe, femur; Fi, fibula; H, humerus; Il, Ilium; IP,
interparietal; Is, ischium; Mc, metacarpus; Ma, mandible; Mt, metatarsus; Mx, maxilla; Na, nasal; O, orbit; P, parietal; Ph, phalanges; Pu, pubis; R,
radius; Sc, scapula; So, supraoccipital; Sq, squamosal; Ta, tarsus; T, tibia; U, ulna
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showed increased fetal viability compared with RV
(75.4% (RE) and 54.4% (RV)). Both SV and SE showed
high rate of fetal viability (96.8% (SV) and 94.6% (SE))
(Table 1, Fig. 3a-c).
RUPP surgery induced fetal growth retardation
reflected by highly significant decrease (p < 0.01) in fetal
body weight and crown rump length in RV group com-
pared with SV group. Nevertheless, maternal injection of
edaravone resulted in significant increase (p < 0.05) in
fetal weight and crown-rump length versus RV group.
There was no statistically significant difference between
fetuses from SV and SE groups (Table 1, Fig. 3d&e).
The placental weight showed insignificant difference
between SV and SE groups. Contrarily, there was a
highly significant decrease in the placental weight in
RV group which was significantly increased after in-
jection with edaravone in the RE group. RV pregnant
mice also showed placental insufficiency reflected by
the decreased fetal to placental weight ratio with only
5.7 compared with the SV ratio of 7.9. It is note-
worthy to mention that injection of edaravone also
significantly increased the fetal to placental weight to
reach 7.2 (Table 1, Fig. 3f&g).
Edaravone decreases the fetal morphological
abnormalities and improves fetus ossification
GD18 fetuses from SV and SE groups showed normal
morphological appearance (Fig. 4a&b). However, RV fe-
tuses showed microtia (Fig. 4c), syndactyly (Fig. 4d), ky-
phosis (Fig. 4e), abdominal subcutanous hemorrhage
(Fig. 4f), unilateral microphthalmia (Fig. 4g) and micro-
cephaly (Fig. 4h). Fetuses from RE group showed more
or less normal morphological structure (Fig. 4i).
Endo-skeleton double staining showed that there was
severe ossification loss in different body parts of RV fe-
tuses, which was improved after edaravone injection
(Fig. 5a). In the skull, only two bones were ossified
compared with SV group which exhibited a large degree
of ossification. This number increased after edaravone
injection in RE group (Fig. 5b). Similarly, only the first
sternabra was ossified in the sternum of RV fetuses,
which increased to four after edaravone injection, while
SV fetuses showed ossification of the whole six sternab-
rae (Fig. 5c).
RV fetuses displayed partial ossification in girdles, sty-
lopodail and zeugopdial bones, however the autopodial
bones didn’t show any ossification at all, in contrast to
the case in SV group which showed high degree of ossi-
fication in all of the bones. This pattern increased after
edaravone injection, although the autopod showed de-
layed ossification compared with SV group (Fig. 5d&e).
The sacrum in RV fetuses remained completely cartil-
aginous unlike that of SV group. Edaravone injection
partially restored the sacral ossification compared with
RV group (Fig. 5f). SE fetuses showed similar ossification
pattern with SV group.
There was no significant difference in the mean
length of bone ossification centers from RV and SV
fetuses. Conversely, RV fetuses showed highly signifi-
cant decrease in ossification centers in all bones com-
pared with SV group. Nevertheless, there was a highly
significant increase in the ossification centers after
edaravone injection compared with RV and significant
decrease (p < 0.05) compared with SV group (Table 2,
Fig. 2S).
Edaravone improved maternal parameters and decreased
the expression of cleaved caspase-3 in the maternal
kidney
RUPP surgery induced hypertension in the mothers as it
significantly increased SBP, DBP and MBP in RUPP ve-
hicle versus sham vehicle groups. Edaravone injection
significantly decreased these values, though still higher
than that of the SV group. Meanwhile, there was no
Table 2 Effect of edaravone injection on the lengths (cm) of ossified centers of the long bones in GD18 mice fetuses subjected to
RUPP placental ischemia
SV SE RV RE
Scapula 0.356 ± 0.018 0.342 ± 0.016 0.122 ± 0.008** 0.246 ± 0.023*##
Humerus 0.344 ± 0.009 0.326 ± 0.017 0.054 ± 0.009** 0.186 ± 0.011*##
Ulna 0.366 ± 0.015 0.348 ± 0.007 0.032 ± 0.008** 0.196 ± 0.014*##
Radius 0.292 ± 0.013 0.242 ± 0.017 0.020 ± 0.007** 0.158 ± 0.013##
Ilium 0.224 ± 0.011 0.202 ± 0.008 0.016 ± 0.005** 0.142 ± 0.010##
Ischium 0.148 ± 0.006 0.118 ± 0.008 0 0.038 ± 0.008*##
Femur 0.278 ± 0.008 0.248 ± 0.006 0.044 ± 0.013** 0.156 ± 0.016*##
Tibia 0.372 ± 0.009 0.351 ± 0.007 0.046 ± 0.011** 0.212 ± 0.016*##
Fibula 0.342 ± 0.008 0.316 ± 0.012 0 0.174 ± 0.015*##
Data are represented as mean (cm) ± SD
* p < 0.05 ** p < 0.01 compared with the SV group
## p < 0.01 compared with RV group. n = 5
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significant difference in all blood pressure parameters
between SV and SE groups (Table 3, Fig. 3S A).
Regarding kidney functions, RUPP significantly in-
creased the levels of maternal serum urea and cre-
atinine with an increase percentage of 52.8 and 88.9,
respectively compared with SV group. Contrarily,
there was a highly significant decrease in urea and
creatinine concentration after edaravone injection
compared with RV group with an increase percent-
age of 16.2 and 22.6 for urea and creatinine, respect-
ively, compared with SV group. No significant
difference was found between SE and SV groups
(Table 4, Fig. 3S B).
Histopathological examination of maternal kidney
showed that both SV and SE groups had normal
structure (Fig. 6a-d). On the other hand, adult kidney
RV group showed capillary occlusion (Fig. 6e-j),
endotheliosis (Fig. 6e), bleeding (Fig. 6f,g,i&j), occa-
sionally aggregation of leukocytes (Fig. 6j), swelling of
glomerulus with increase in cellularity (Fig. 6e&f) or
shrinkage of glomerulus with widened bowman’s
space (Fig. 6g&h), in addition to detached renal cells
from degenerated tubules (Fig. 6g). However, all these
alterations, except for capillary occlusion, were atten-
uated after edaravone injection in the RE group (Fig.
6k&l).
The maternal heart from both SV and SE groups
showed well-arranged myocardial fibers (Fig. 7a&b for
SV and SE groups, respectively). In contrast, the ma-
ternal heart from SV group showed focal myocyte ne-
crosis (Fig. 7c-h), irregular myocardial fibers (Fig. 7c),
wide myocardial gaps with macrophages (Fig. 7d),
rippled myocytes with cell mobilization in the degen-
erating myocardial fibers (Fig. 7f&g) and hemorrhagic
foci (Fig. 7h). Interestingly, edaravone injection re-
sulted in improvement of the cardiac structure with
minimal foci of damaged myocytes and a small ir-
regularity in the muscle fibers (Fig. 7i).
Due to increased urea and creatinine levels in the
blood suggesting malfunction of the maternal kid-
ney, Caspase-3 immunohistochemical staining was
adopted to investigate apoptosis. The expression of
cleaved caspase-3 showed a high significant increase
in the renal tubules and glomeruli of the kidney of
pregnant mice subjected to RUPP with a mean per-
centage area expression of 30.1 compared with 4.8
in RV group. However, after edaravone injection the
expression significantly decreased to 11.6%, though
there was still significant increase compared with
RV group. Meanwhile, there was insignificant differ-
ence between RV and RE groups (Fig. 8). The ex-
pression of cleaved caspase-3 in the maternal heart
showed no significant difference among the four
groups with low levels of expression (data not
shown).
Discussion
In the current study, RUPP induced severe reduction
in pregnant mice weight which was accompanied by
decreased uterine weights, increased fetal loss and
resorption, as well as fetal growth retardation and
decreased feto/placental ratio. Previous findings
ascertained that RUPP induced maternal weight loss
in different models [1, 17, 25, 50] accompanied by
fetal growth retardation and decreased placental
weight. According to Farag et al. [14], maternal and
uterine weights decrease could be attributed to fetal
intrauterine growth restriction and fetal loss. Fetal
growth retardation is a hallmark of preeclampsia
which is attributed to reduced placental blood flow
to the growing fetus resulting in placental ischemia
and as a consequence, reduction of maternal-fetal
oxygen exchange and nutrients affecting fetal growth
and development [19, 54].
Table 4 Serum levels of urea and creatinine of pregnant mice in different groups
SV SE RV RE
Urea conc. (mg/dl) 22.1 ± 0.13 23.4 ± 0.19 31.5 ± 0.15** 25.6 ± 0.14*#
Percentage of increase % 0 5.88% 42.5% 15.8%
Creatinine Conc. (mg/dl) 2.9 ± 0.11 3.1 ± 0.12 5.4 ± 0.14** 3.5 ± 0.11*#
Percentage of increase % 0 6.9% 86.2% 20.6%
Data are represented as mean ± SD
* p < 0.05 ** p < 0.01 compared with the SV group
# p < 0.05 ## p < 0.01 compared with RV group. n = 5
Table 3 systolic, diastolic and mean blood pressure (mmHg) of
pregnant mice from different groups at GD 18
SBP DBP MBP
SV 115.6 ± 3.162 79.2 ± 2.236 97.4 ± 2.573
SE 117.3 ± 2.915 80.7 ± 6.164 99 ± 2.850
RV 149.5 ± 4.123** 113.4 ± 6.016** 131.45 ± 1.917**
RE 128.2 ± 2.701*## 98.1 ± 4.929*# 113.15 ± 2.329*##
Data are represented as mean ± SD
* p < 0.05 ** p < 0.01 compared with the SV group
# p < 0.05 ## p < 0.01 compared with RV group. n = 5
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Edaravone injection (3 mg/kg), in the current study,
significantly increased the body weight gain of the
mothers, significantly increased the fetal crown-rump
length, weight, placental weight and feto/placental ra-
tio. Edaravone is an established free radical scavenger
which has a hydroxyl radical quenching effect and an
inhibitory effect against peroxynitrite and peroxyl rad-
icals [53]. One of the important factors leading to
fetal growth restriction in preeclampsia is the in-
creased production of placental oxidants due to in-
creased maternal and fetal metabolism [10, 48]. The
role of antioxidants in management of placental
ischemia-induced growth retardation and decreased
placental weight has been investigated [36, 43, 52].
Moreover, Ushida et al. [50] found that maternal ad-
ministration of the novel antioxidant compound H2
to RUPP rats increased the fetal and placental
weights. H2, same as edaravone, selectively reduces
peroxynitirite, which has a pathological role on pre-
eclampsia [29].
Mice fetuses of RUPP group in the current study
showed many morphological abnormalities which
could be attributed to the induced placental hypoxia
according to Ritchie et al. [38] who reported that
hypoxia induced by clamping of uterine arteries
resulted in morphological malformations. Meanwhile,
the fetuses of RUPP group, in the current study,
showed severe delayed ossification and decreased
length of ossified centers in different bones. Many
studies had related disrupted bone development and
skeletal abnormalities with fetal growth restriction [6,
39]. Additionally, hypoxia may play role in altered
bone development [9, 51].
Interestingly, edaravone injection, in the present
study, resulted in better morphological features of the
fetuses, increased the fetal weight and length and in-
creased the degree of ossification and length of ossi-
fied centers, though some skeletal structures showed
delayed ossification compared with sham group. The
cytoprotective effect of edaravone on bone and osteo-
blast survival through its ROS-scavenging ability has
been reported in many studies [8, 46], moreover, the
authors suggested that edaravone may have antiosteo-
porosis potential.
The present study showed that RUPP resulted in
maternal hypertension, in addition, the maternal
heart manifested many histopathological alterations.
Maternal hypertension and cardiac abnormalities
have been associated with RUPP procedure [17, 18,
23, 27], which can be attributed to placental
Fig. 6 Representative photomicrographs of H&E stained transverse sections of maternal kidney from different groups. a&b SV group c&d SE
group showing normal structure. f-g RV group showing endotheliosis (thick arrow), glomerulus swelling (black arrowhead), hemorrhage (h),
shrunken glomerulus (white arrowhead), widened bowman’s space (*), and detached renal cells from degenerated tubules (arrow). k&l RE group
showing improved renal structure after edaravone injection. DT; distal convoluted tubules, G; glomerulus, h; hemorrhage; Li; leukocytic infiltration,
PT; proximal convoluted tubule
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oxidative damage and angiogenic imbalance [50].
Preeclampsia was reported to be associated with car-
diac dysfunction and increased risk of myocardial in-
farction as well as heart failure [4, 31]. Additionally,
hypertension, itself, can greatly increase the risk of
cardiovascular diseases [7].
Edaravone injection, in the current study, attenuated
that increase in blood pressure and the cardiac structure.
Many studies have addressed the effectiveness of edara-
vone as a cardio-protectant, especially in ischemia/reper-
fusion injury [33, 45, 55], possibly via its hydroxyl
radicals quenching properties [12] and its anti-
inflammatory effect [26]. The maternal blood urea and
creatinine levels were significantly increased in this
study, this was accompanied by renal histopathological
alterations in the RUPP mothers. Similar results showed
that RUPP in pregnant mice resulted in increased albu-
min/creatinine ratio, endotheliosis, bleeding, glomerular
swelling and mesangial expansion [17, 50]. Glomerular
endotheliosis is usually a characteristic feature of pre-
eclampsia [44]. It was suggested that increased oxidative
stress can have deleterious effects on renal function in
the RUPP model [5, 40]. In line with that, edaravone
injection restored the renal functions and attenuated
the renal structure. Edaravone was reported to ameli-
orate the renal ischemia/reperfusion injury and de-
creasing blood urea and creatinine possibly by
scavenging the free radicals in the renal tubes and in-
hibition of lipid peroxidation [13]. In addition, edara-
vone alleviated the RUPP induced apoptosis in the
maternal kidney as it decreased the expression of
cleaved caspase-3. Previous reports showed the anti-
apoptotic effect of edaravone and decreased caspase-3
expression in different ischemia models and attributed
this effect to its free radical and ROS scavenging abil-
ities [2, 16, 57].
In conclusion, the present study demonstrated that the
RUPP-induced placental ischemia in the mice resulted
Fig. 7 Representative photomicrographs of H&E stained longitudinal sections of maternal heart from different groups. Normal histological
structure of heart from SV (a) and SE (b) groups. Maternal heart from RV group (c-h) showing irregular myocardial fibers (c), widened gaps
between fibers with macrophage (arrow, d), necrotic foci (asterisk, e-g), cell mobilization from rippled muscle fibers (arrowhead, f&g), hemorrhage
(h) within degenerated myofibrils (h). Improved heart structure after edaravone injection in the RE group (i). h; hemorrhage, MF; myocardial fibers,
MG; myocardial gap, MN; myocardial nuclei
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in preeclampsia-related symptoms. Notably, edaravone
injection attenuated most of these symptoms possibly
due to its antioxidant and free radical scavenging ability.
These results suggest the potential efficacy of edaravone
as an adjuvant therapy for preeclampsia. However, fur-
ther studies are needed to understand its actual mechan-
ism of action during preeclampsia, as well as its safety
for clinical use, to validate its application in the future.
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